Biotechnology company Sygnis AG plans to acquire proteomics company Expedeon to expand its product portfolio and develop sales in the US and European markets.

The company has announced its plans to raise funds amounting to $23.4m by issuing rights offerings of up to 20,538,089 shares, and has further announced an offering of the unsubscribed new shares to the Expedeon shareholders.

Incyte has entered an agreement with ARIAD Pharmaceuticals to acquire all the shares and European operations of ARAID.

The agreement allows Incyte to develop its European medical and commercial market and ARIAD Pharmaceutical to strengthen its financial position and commercialise Iclusig in the US.

Iclusig is indicated for the treatment of T315I-positive chronic myeloid leukemia (CML) or T315I-positive, Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adult patients.

Aptuit plans to expand its formulation development capabilities in pre-formulation, formulation prototyping and formulation development service, through the acquisition of Kuepcept LTD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The former is a pharmaceutical services company and the latter is a UK-based, drug development service provider.